BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37886854)

  • 1. The single-cell evolution trajectory presented different hypoxia heterogeneity to reveal the carcinogenesis of genes in clear cell renal cell carcinoma: Based on multiple omics and real experimental verification.
    Ma B; Qin L; Sun Z; Wang J; Tran LJ; Zhang J; Ye F; Liu Y; Chen M
    Environ Toxicol; 2024 Feb; 39(2):869-881. PubMed ID: 37886854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell transcriptome analysis revealing the intratumoral heterogeneity of ccRCC and validation of MT2A in pathogenesis.
    Wang J; Zuo Z; Yu Z; Chen Z; Meng X; Ma Z; Niu J; Guo R; Tran LJ; Zhang J; Jiang T; Ye F; Ma B; Sun Z
    Funct Integr Genomics; 2023 Sep; 23(4):300. PubMed ID: 37713131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma.
    Zhang D; Ni Y; Wang Y; Feng J; Zhuang N; Li J; Liu L; Shen W; Zheng J; Zheng W; Qian C; Shan J; Zhou Z
    J Transl Med; 2023 Jul; 21(1):489. PubMed ID: 37474942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-associated macrophage-derived chemokine CCL5 facilitates the progression and immunosuppressive tumor microenvironment of clear cell renal cell carcinoma.
    Xu W; Wu Y; Liu W; Anwaier A; Tian X; Su J; Huang H; Wei G; Qu Y; Zhang H; Ye D
    Int J Biol Sci; 2022; 18(13):4884-4900. PubMed ID: 35982911
    [No Abstract]   [Full Text] [Related]  

  • 5. RP11-367G18.1 V2 enhances clear cell renal cell carcinoma progression via induction of epithelial-mesenchymal transition.
    Shao IH; Peng PH; Wu HH; Chen JL; Lai JC; Chang JS; Wu HT; Wu KJ; Pang ST; Hsu KW
    Cancer Med; 2023 Apr; 12(8):9788-9801. PubMed ID: 36847128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unraveling the prognostic significance and molecular characteristics of tumor-infiltrating B lymphocytes in clear cell renal cell carcinoma through a comprehensive bioinformatics analysis.
    Yue Y; Cai X; Lu C; Sechi LA; Solla P; Li S
    Front Immunol; 2023; 14():1238312. PubMed ID: 37908350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HnRNP A1 - mediated alternative splicing of CCDC50 contributes to cancer progression of clear cell renal cell carcinoma via ZNF395.
    Sun G; Zhou H; Chen K; Zeng J; Zhang Y; Yan L; Yao W; Hu J; Wang T; Xing J; Xiao K; Wu L; Ye Z; Xu H
    J Exp Clin Cancer Res; 2020 Jun; 39(1):116. PubMed ID: 32560659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ubiquitin-specific peptidase 53 inhibits the occurrence and development of clear cell renal cell carcinoma through NF-κB pathway inactivation.
    Gui D; Dong Z; Peng W; Jiang W; Huang G; Liu G; Ye Z; Wang Y; Xu Z; Fu J; Luo S; Zhao Y
    Cancer Med; 2021 Jun; 10(11):3674-3688. PubMed ID: 33973730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
    Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
    J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive intratumoral heterogeneity landscaping of liver hepatocellular carcinoma and discerning of APLP2 in cancer progression.
    Tao Z; Huang J; Li J
    Environ Toxicol; 2024 Feb; 39(2):612-625. PubMed ID: 37515494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Activation of HIF-1α/ACLY signaling axis promotes progression of clear cell renal cell carcinoma with VHL inactivation mutation].
    Ma Y; Wang YH; Huang S; Zou ZG; Hu L; Guo LC
    Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1230-1236. PubMed ID: 38058039
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of single-cell RNA-seq and bulk RNA-seq revealed the heterogeneity and convergence of the immune microenvironment in renal cell carcinoma.
    Lv S; Tao L; Liao H; Huang Z; Lu Y
    Funct Integr Genomics; 2023 Jun; 23(2):193. PubMed ID: 37264263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a polyamine gene expression score for predicting prognosis and treatment response in clear cell renal cell carcinoma.
    Chen M; Nie Z; Huang D; Gao Y; Cao H; Zheng L; Zhang S
    Front Immunol; 2022; 13():1048204. PubMed ID: 36505496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein Arginine Methyltransferases Refine the Classification of Clear Cell Renal Cell Carcinoma with Distinct Prognosis and Tumor Microenvironment Characteristics.
    Ye S; Tian X; Anwaier A; Wei S; Liu W; Su J; Zhu S; Dai B; Gu J; Qu Y; Xu W; Zhang H; Ye D
    Int J Biol Sci; 2023; 19(14):4552-4570. PubMed ID: 37781030
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins.
    Stoyanoff TR; Rodríguez JP; Todaro JS; Espada JD; Colavita JP; Brandan NC; Torres AM; Aguirre MV
    Tumour Biol; 2016 Oct; 37(10):13581-13593. PubMed ID: 27468719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance and oncogenic function of NR1H4 in clear cell renal cell carcinoma.
    Huang S; Hou Y; Hu M; Hu J; Liu X
    BMC Cancer; 2022 Sep; 22(1):995. PubMed ID: 36123627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
    Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
    Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Ligand-Receptor Pairs Associated With Tumour Characteristics in Clear Cell Renal Cell Carcinoma.
    Liu F; Wang P; Sun W; Jiang Y; Gong Q
    Front Immunol; 2022; 13():874056. PubMed ID: 35734169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved therapy for clear cell renal cell carcinoma: beta-hydroxybutyrate and quercetin target hypoxia-induced angiogenesis and multidrug resistance.
    Mohammadipoor N; Naiebi R; Mazhari SA; Amooei F; Owrang M; Dastghaib S; Shams M; Maleki MH; Dastghaib S
    Mol Biol Rep; 2024 Mar; 51(1):379. PubMed ID: 38429605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.